Clinical Trial Results:
Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer.
A multicenter, randomized phase III trial.
Summary
|
|
EudraCT number |
2018-003648-22 |
Trial protocol |
BE AT |
Global end of trial date |
15 Apr 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Jun 2022
|
First version publication date |
26 Jun 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SAKK_2118
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03905343 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Swiss Group for Clinical Cancer Research (SAKK)
|
||
Sponsor organisation address |
Effingerstrasse 33, Bern, Switzerland, 3008
|
||
Public contact |
Head Regulatory Affairs, Swiss Group for Clinical Cancer, +41 31389 91 91, sakkcc@sakk.ch
|
||
Scientific contact |
Head Regulatory Affairs, Swiss Group for Clinical Cancer, +41 31389 91 91, sakkcc@sakk.ch
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
10 Dec 2021
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Apr 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Apr 2021
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The aim of this trial is to assess if patients treated with the combination of ribociclib and endocrine therapy respond to treatment as fast as patients treated with chemotherapy only, without decreasing their quality of life (QoL).
|
||
Protection of trial subjects |
Protection of trial subjects was ensured by Safety Monitoring, i.e. assessment of adverse events, serious adverse events, adverse drug reactions, and the continous assessment of laboratory values and vital signs.
|
||
Background therapy |
None | ||
Evidence for comparator |
Mono-chemotherapy according to local guidelines for at least 12 weeks or until progression was used as reference therapy. The choice of mono-chemotherapy was up to the investigator. It had to be registered and reimbursed by health insurances. Metronomic chemotherapy, combination chemotherapy and antiangiogenic therapy was not allowed. | ||
Actual start date of recruitment |
26 Aug 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 1
|
||
Country: Number of subjects enrolled |
Switzerland: 24
|
||
Worldwide total number of subjects |
25
|
||
EEA total number of subjects |
1
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
10
|
||
From 65 to 84 years |
15
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
The recruitment phase started on 26-Aug-2019 and was prematurely stopped due to financial reasons on 25-Nov-2021 after the recruitment of 25 out of 400 planned patients. Last patient was enrolled on 12-Nov-2020. Twenty-four patients at ten centres were enrolled in Switzerland and one patient in Belgium. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Eligibility criteria of a patient were checked by the investigator. Once a patient fullfils all inclusion criteria and not any of the exclusion criteria, he/she was randomized. | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Baseline
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Arm A | ||||||||||||||||||||||||
Arm description |
Ribociclib and endocrine therapy. The selection of endocrine treatment was according to local guidelines and depended on registration and reimbursement by the health insurance. Endocrine therapy consisted of a registered aromatase inhibitor or fulvestrant, only if reimbursed by the health insurance. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Ribociclib
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
Kisqali®
|
||||||||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
600 mg p.o. on day 1 to day 21, q4w
|
||||||||||||||||||||||||
Investigational medicinal product name |
Endocrine therapy (according to local quidelines)
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Not assigned
|
||||||||||||||||||||||||
Routes of administration |
Not mentioned
|
||||||||||||||||||||||||
Dosage and administration details |
According to local guidelines.
|
||||||||||||||||||||||||
Arm title
|
Arm B | ||||||||||||||||||||||||
Arm description |
Mono-chemotherapy for at least 12 weeks or until progression. Chemotherapy had to be given according to local guidelines. The choice of mono-chemotherapy was up to the investigator. It had to be registered and reimbursed by health insurances. Metronomic chemotherapy, combination chemotherapy and antiangiogenic therapy was not allowed. After at least 12 weeks and no PD, the investigator could perform a riskbenefit assessment and decide whether to continue the chemotherapy or to start a maintenance endocrine therapy with or without ribociclib. | ||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||
Investigational medicinal product name |
Mono-chemotherapy
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Not assigned
|
||||||||||||||||||||||||
Routes of administration |
Not mentioned
|
||||||||||||||||||||||||
Dosage and administration details |
Chemotherapy had to be given according to local guidelines.
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||
Period 2 title |
Treatment Phase
|
||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Arm A | ||||||||||||||||||||||||
Arm description |
Ribociclib and endocrine therapy. The selection of endocrine treatment was according to local guidelines and depended on registration and reimbursement by the health insurance. Endocrine therapy consisted of a registered aromatase inhibitor or fulvestrant, only if reimbursed by the health insurance. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Ribociclib
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
Kisqali®
|
||||||||||||||||||||||||
Pharmaceutical forms |
Coated tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
600 mg p.o. on day 1 to day 21, q4w
|
||||||||||||||||||||||||
Investigational medicinal product name |
Endocrine therapy (according to local quidelines)
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Not assigned
|
||||||||||||||||||||||||
Routes of administration |
Not mentioned
|
||||||||||||||||||||||||
Dosage and administration details |
According to local guidelines.
|
||||||||||||||||||||||||
Arm title
|
Arm B | ||||||||||||||||||||||||
Arm description |
Mono-chemotherapy for at least 12 weeks or until progression. Chemotherapy had to be given according to local guidelines. The choice of mono-chemotherapy was up to the investigator. It had to be registered and reimbursed by health insurances. Metronomic chemotherapy, combination chemotherapy and antiangiogenic therapy was not allowed. After at least 12 weeks and no PD, the investigator could perform a riskbenefit assessment and decide whether to continue the chemotherapy or to start a maintenance endocrine therapy with or without ribociclib. | ||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||
Investigational medicinal product name |
Mono-chemotherapy
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Not assigned
|
||||||||||||||||||||||||
Routes of administration |
Not mentioned
|
||||||||||||||||||||||||
Dosage and administration details |
Chemotherapy had to be given according to local guidelines.
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Arm A
|
||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Ribociclib and endocrine therapy. The selection of endocrine treatment was according to local guidelines and depended on registration and reimbursement by the health insurance. Endocrine therapy consisted of a registered aromatase inhibitor or fulvestrant, only if reimbursed by the health insurance. | ||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Arm B
|
||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Mono-chemotherapy for at least 12 weeks or until progression. Chemotherapy had to be given according to local guidelines. The choice of mono-chemotherapy was up to the investigator. It had to be registered and reimbursed by health insurances. Metronomic chemotherapy, combination chemotherapy and antiangiogenic therapy was not allowed. After at least 12 weeks and no PD, the investigator could perform a riskbenefit assessment and decide whether to continue the chemotherapy or to start a maintenance endocrine therapy with or without ribociclib. | ||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Arm A
|
||
Reporting group description |
Ribociclib and endocrine therapy. The selection of endocrine treatment was according to local guidelines and depended on registration and reimbursement by the health insurance. Endocrine therapy consisted of a registered aromatase inhibitor or fulvestrant, only if reimbursed by the health insurance. | ||
Reporting group title |
Arm B
|
||
Reporting group description |
Mono-chemotherapy for at least 12 weeks or until progression. Chemotherapy had to be given according to local guidelines. The choice of mono-chemotherapy was up to the investigator. It had to be registered and reimbursed by health insurances. Metronomic chemotherapy, combination chemotherapy and antiangiogenic therapy was not allowed. After at least 12 weeks and no PD, the investigator could perform a riskbenefit assessment and decide whether to continue the chemotherapy or to start a maintenance endocrine therapy with or without ribociclib. | ||
Reporting group title |
Arm A
|
||
Reporting group description |
Ribociclib and endocrine therapy. The selection of endocrine treatment was according to local guidelines and depended on registration and reimbursement by the health insurance. Endocrine therapy consisted of a registered aromatase inhibitor or fulvestrant, only if reimbursed by the health insurance. | ||
Reporting group title |
Arm B
|
||
Reporting group description |
Mono-chemotherapy for at least 12 weeks or until progression. Chemotherapy had to be given according to local guidelines. The choice of mono-chemotherapy was up to the investigator. It had to be registered and reimbursed by health insurances. Metronomic chemotherapy, combination chemotherapy and antiangiogenic therapy was not allowed. After at least 12 weeks and no PD, the investigator could perform a riskbenefit assessment and decide whether to continue the chemotherapy or to start a maintenance endocrine therapy with or without ribociclib. | ||
Subject analysis set title |
Arm A
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
FAS = PPS
The FAS was defined as all randomized patients who received at least one dose of trial treatment excluding patients with major eligibility violations. Following the intention-to-treat principle, patients in this set were analyzed according to the treatment they were randomized to.
|
||
Subject analysis set title |
Arm B
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
FAS = PPS
The FAS was defined as all randomized patients who received at least one dose of trial treatment excluding patients with major eligibility violations. Following the intention-to-treat principle, patients in this set were analyzed according to the treatment they were randomized to.
One patient had a second tumor present at baseline, which was detected when the patient was already on trial treatment. The patient violated inclusion criterion 6.1.6 and was excluded from FAS (and PPS).
|
|
|||||||||||||||||||||||||
End point title |
PE - Quality of life adjusted early disease control (composite EP - 1a/2 Disease Control - Response at week 12) [1] | ||||||||||||||||||||||||
End point description |
The primary enpoint, quality of life-adjusted early disease control at 12 weeks is a composite endpoint. The first component is disease control (CR, PR or SD according to RECIST v1.1) at 12 weeks (+1 week for delayed assessments).
If a patient had no assessment at 12 weeks but CR, PR or SD thereafter it was counted as SD at 12 weeks.
The second component was defined as follows: FACTB TOI score does not worsen by 5 points or more during the first 12 weeks after randomization (+1 week for delayed assessments).
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Responses at week 12
|
||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the low sample size, statistical analysis was not performed and data were analyzed descriptively. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
PE - Quality of life adjusted early disease control (composite EP - 1b/2 Disease Control - Disease control at week 12) [2] | ||||||||||||||||||
End point description |
The primary enpoint, quality of life-adjusted early disease control at 12 weeks is a composite endpoint. The first component is disease control (CR, PR or SD according to RECIST v1.1) at 12 weeks (+1 week for delayed assessments).
If a patient had no assessment at 12 weeks but CR, PR or SD thereafter it was counted as SD at 12 weeks.
The second component was defined as follows: FACTB TOI score does not worsen by 5 points or more during the first 12 weeks after randomization (+1 week for delayed assessments).
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Disease control at week 12.
|
||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the low sample size, statistical analysis was not performed and data were analyzed descriptively. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
PE - Quality of life adjusted early disease control (composite EP - 2/2 FACT-B TOI worsening during first 12 weeks) [3] | |||||||||||||||||||||
End point description |
The primary enpoint, quality of life-adjusted early disease control at 12 weeks is a composite endpoint. The first component is disease control (CR, PR or SD according to RECIST v1.1) at 12 weeks (+1 week for delayed assessments).
If a patient had no assessment at 12 weeks but CR, PR or SD thereafter it was counted as SD at 12 weeks.
The second component was defined as follows: FACTB TOI score does not worsen by 5 points or more during the first 12 weeks after randomization (+1 week for delayed assessments).
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
TOI worsening of at least 5 points within first 12 weeks
|
|||||||||||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the low sample size, statistical analysis was not performed and data were analyzed descriptively. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
PE - Quality of life adjusted early disease control (composite EP - Composite) [4] | ||||||||||||||||||
End point description |
The primary enpoint, quality of life-adjusted early disease control at 12 weeks is a composite endpoint. The first component is disease control (CR, PR or SD according to RECIST v1.1) at 12 weeks (+1 week for delayed assessments).
If a patient had no assessment at 12 weeks but CR, PR or SD thereafter it was counted as SD at 12 weeks.
The second component was defined as follows: FACTB TOI score does not worsen by 5 points or more during the first 12 weeks after randomization (+1 week for delayed assessments).
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Composite of quality of life-adjusted disease control at week 12
|
||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the low sample size, statistical analysis was not performed and data were analyzed descriptively. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PE - Quality of life adjusted early disease control (composite EP - Composite rate) [5] | ||||||||||||
End point description |
The primary enpoint, quality of life-adjusted early disease control at 12 weeks is a composite endpoint. The first component is disease control (CR, PR or SD according to RECIST v1.1) at 12 weeks (+1 week for delayed assessments).
If a patient had no assessment at 12 weeks but CR, PR or SD thereafter it was counted as SD at 12 weeks.
The second component was defined as follows: FACTB TOI score does not worsen by 5 points or more during the first 12 weeks after randomization (+1 week for delayed assessments).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Composit quality of life-adjusted disease control rate at week 12
|
||||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to the low sample size, statistical analysis was not performed and data were analyzed descriptively. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
SE - Disease control at week 12 | ||||||||||||
End point description |
Disease control at week 12 (see also primary endpoint)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
12 weeks
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
SE - Objective response rate (ORR) 1/2 Best overall response | |||||||||||||||||||||
End point description |
Best overall response according to RECIST v1.1, i.e. CR/PR rates
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
From Baseline until EoS
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
SE - Objective response rate (ORR) 2/2 Objective response rate | ||||||||||||
End point description |
Objective response rate
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline until EoS.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
SE - Objective response rate (ORR) - Time to objective response | ||||||||||||
End point description |
Time to event analysis (Kaplan-Meier) for patient with ORR partial response; 8 patients in arm A and 4 in arm B reached PR.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time to event from enrollment.
|
||||||||||||
|
|||||||||||||
Notes [6] - Analysis only for patients with ORR = PR. [7] - Analysis only for patients with ORR = PR. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
SE - Progression-free survival (PFS) | ||||||||||||
End point description |
Time to event analysis (Kaplan-Meier) for progression-free survival (PFS); 6 patients in arm A and 6 in arm B had experienced disease progression.
NOTE: UPPER LIMITS FOR 95% CI FOR MEDIAN PFS WERE NOT REACHED. HOWEVER, DUMMY VALUES FOR UPPER 95% CI LIMITS ENTERED DUE TO DATABASE RESTRICTIONS.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time to event from enrollment.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
SE - Time to treatment failure (TTF) | ||||||||||||
End point description |
Time to event analysis (Kaplan-Meier) for time to treatment failure (TTF); all patients stopped trial treatment before the planned 3 years of treatment. One patient in arm A and one in arm B were treated beyond progression (see Section 6.5). For these patients TTF was longer than PFS.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time to event from enrollment.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
SE - Overall survival (OS) | ||||||||||||
End point description |
Time to event analysis (Kaplan-Meier) for overall survival (OS); two patients in arm A and one patient in arm B had died.
NOTE: MEDIAN OS TIMES WERE NOT REACHED. DUMMY DATA ENTERED DUE TO DATABASE RESTRICTIONS.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Time to event from enrollment.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From enrollment until EoS.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Arm A (SAF)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Arm B (SAF)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
The study was terminated prematurely by the sponsor. All patients stopped trial treatment before the planned three years of treatment. The sample size was low (planned 400 patients; actual: 25 patients). Thus data have to be interpreted with caution. |